<DOC>
	<DOCNO>NCT01712074</DOCNO>
	<brief_summary>This study evaluate safety efficacy PF-05212377 subject mild-to-moderate Alzheimer 's Disease exist neuropsychiatric symptom stable dose Donepezil . The 4-week run-in minimize placebo effect . The 12-week treatment period consider minimum length necessary reliably evaluate effect PF-05212377 cognition neuropsychiatric symptom population . The 2-week washout allow monitor re-emergence neuropsychiatric cognitive symptom .</brief_summary>
	<brief_title>Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer 's Disease With Existing Neuropsychiatric Symptoms On Donepezil</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Clinical diagnosis probable AD supportive brain image documentation Have exist neuropsychiatric symptom define score equal great 10 NPI screening , arise item score equal great 2 ( frequency X severity ) least 2 domain . Has donepezil ( stable dose 5 mg 10 mg ) least four month , intent change duration study . Demonstrate extreme agitation , physical aggression violence , caregiver , others , and/or inability complete ADAScog assessment Screening . Have major structural brain disease Alzheimer 's Disease Other severe acute chronical medical psychiatric condition laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Safety Efficacy</keyword>
</DOC>